Alterity Therapeutics
ATHE
21 hedge funds and large institutions have $2.12M invested in Alterity Therapeutics in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 0 closing their positions.
89% more capital invested
Capital invested by funds: $1.12M → $2.12M (+$1,000K)
40% more funds holding
Funds holding: 15 → 21 (+6)
0.41% more ownership
Funds ownership: 1.77% → 2.18% (+0.41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GT
Greenleaf Trust
Kalamazoo,
Michigan
|
+$131K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$76.2K |
| 3 |
HF
HRT Financial
New York
|
+$75.2K |
| 4 |
Morgan Stanley
New York
|
+$20.4K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$14.9K |
Top Sellers
ATHE Hedge Fund Activity: Q2 2026 in Review
21 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q2 2026, worth a combined $2.12M — up 89% from $1.12M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ATHE positions and 0 closed out — a net gain of 6 holders — while 7 added to existing stakes and 0 trimmed.
The largest buyer was Greenleaf Trust, adding an estimated $131K.
- 21 institutional investors held Alterity Therapeutics (ATHE) as of Q2 2026, up from 15 in Q1 2026.
- Funds reported $2.12M of Alterity Therapeutics stock for Q2 2026, up 89% quarter-over-quarter.
- 6 funds opened new Alterity Therapeutics positions in Q2 2026 and 0 closed out, a net change of +6 holders.
- The largest Alterity Therapeutics buyer in Q2 2026 was Greenleaf Trust, an estimated $131K added.
Based on aggregated 13F filings for Q2 2026.